BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jackson RA, Chen ES. Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs. Pharmacology & Therapeutics 2016;162:69-85. [DOI: 10.1016/j.pharmthera.2016.01.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Gorecki L, Andrs M, Korabecny J. Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer. Cancers (Basel) 2021;13:795. [PMID: 33672884 DOI: 10.3390/cancers13040795] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
2 Efferth T, Saeed MEM, Mirghani E, Alim A, Yassin Z, Saeed E, Khalid HE, Daak S. Integration of phytochemicals and phytotherapy into cancer precision medicine. Oncotarget 2017;8:50284-304. [PMID: 28514737 DOI: 10.18632/oncotarget.17466] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 10.5] [Reference Citation Analysis]
3 O'Neil NJ, Bailey ML, Hieter P. Synthetic lethality and cancer. Nat Rev Genet 2017;18:613-23. [PMID: 28649135 DOI: 10.1038/nrg.2017.47] [Cited by in Crossref: 236] [Cited by in F6Publishing: 198] [Article Influence: 47.2] [Reference Citation Analysis]
4 Feng L, Wang G, Chen Y, He G, Liu B, Liu J, Chiang CM, Ouyang L. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives. Med Res Rev 2021. [PMID: 34633088 DOI: 10.1002/med.21859] [Reference Citation Analysis]
5 Jariyal H, Weinberg F, Achreja A, Nagarath D, Srivastava A. Synthetic lethality: a step forward for personalized medicine in cancer. Drug Discovery Today 2020;25:305-20. [DOI: 10.1016/j.drudis.2019.11.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
6 Ren B, Chen ES. Regulation of centromeric heterochromatin in the cell cycle by phosphorylation of histone H3 tyrosine 41. Curr Genet 2019;65:829-36. [DOI: 10.1007/s00294-019-00962-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Seah KS, Loh JY, Nguyen TTT, Tan HL, Hutchinson PE, Lim KK, Dymock BW, Long YC, Lee EJD, Shen HM, Chen ES. SAHA and cisplatin sensitize gastric cancer cells to doxorubicin by induction of DNA damage, apoptosis and perturbation of AMPK-mTOR signalling. Exp Cell Res. 2018;370:283-291. [PMID: 29959912 DOI: 10.1016/j.yexcr.2018.06.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
8 Kotelnikova EA, Pyatnitskiy M, Paleeva A, Kremenetskaya O, Vinogradov D. Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine. Oncotarget 2016;7:52493-516. [PMID: 27191992 DOI: 10.18632/oncotarget.9370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Hoong BYD, Gan YH, Liu H, Chen ES. cGAS-STING pathway in oncogenesis and cancer therapeutics. Oncotarget 2020;11:2930-55. [PMID: 32774773 DOI: 10.18632/oncotarget.27673] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
10 Liu C, Zhao J, Lu W, Dai Y, Hockings J, Zhou Y, Nussinov R, Eng C, Cheng F. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes. PLoS Comput Biol 2020;16:e1007701. [PMID: 32101536 DOI: 10.1371/journal.pcbi.1007701] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
11 Jackson RA, Nguyen ML, Barrett AN, Tan YY, Choolani MA, Chen ES. Synthetic combinations of missense polymorphic genetic changes underlying Down syndrome susceptibility. Cell Mol Life Sci 2016;73:4001-17. [PMID: 27245382 DOI: 10.1007/s00018-016-2276-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Gorecki L, Andrs M, Rezacova M, Korabecny J. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. Pharmacol Ther 2020;210:107518. [PMID: 32109490 DOI: 10.1016/j.pharmthera.2020.107518] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
13 Yu T, Choi KP, Chen ES, Zhang L. Stage-specific protein-domain mutational profile of invasive ductal breast cancer. BMC Med Genomics 2020;13:150. [PMID: 33087126 DOI: 10.1186/s12920-020-00777-y] [Reference Citation Analysis]
14 Toma M, Skorski T, Sliwinski T. DNA Double Strand Break Repair - Related Synthetic Lethality. Curr Med Chem 2019;26:1446-82. [PMID: 29421999 DOI: 10.2174/0929867325666180201114306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lam UTF, Chen ES. Molecular mechanisms in governing genomic stability and tumor suppression by the SETD2 H3K36 methyltransferase. Int J Biochem Cell Biol 2022;:106155. [PMID: 34990836 DOI: 10.1016/j.biocel.2021.106155] [Reference Citation Analysis]
16 Poornima P, Kumar JD, Zhao Q, Blunder M, Efferth T. Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. Pharmacol Res 2016;111:290-302. [PMID: 27329331 DOI: 10.1016/j.phrs.2016.06.018] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 10.5] [Reference Citation Analysis]
17 Chen ES. Targeting epigenetics using synthetic lethality in precision medicine. Cell Mol Life Sci 2018;75:3381-92. [PMID: 30003270 DOI: 10.1007/s00018-018-2866-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Leung AW, de Silva T, Bally MB, Lockwood WW. Synthetic lethality in lung cancer and translation to clinical therapies. Mol Cancer 2016;15:61. [PMID: 27686855 DOI: 10.1186/s12943-016-0546-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
19 Shire Z, Vakili MR, Morgan TDR, Hall DG, Lavasanifar A, Weinfeld M. Nanoencapsulation of Novel Inhibitors of PNKP for Selective Sensitization to Ionizing Radiation and Irinotecan and Induction of Synthetic Lethality. Mol Pharm 2018;15:2316-26. [PMID: 29688721 DOI: 10.1021/acs.molpharmaceut.8b00169] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
20 Noor F, Tahir ul Qamar M, Ashfaq UA, Albutti A, Alwashmi ASS, Aljasir MA. Network Pharmacology Approach for Medicinal Plants: Review and Assessment. Pharmaceuticals 2022;15:572. [DOI: 10.3390/ph15050572] [Reference Citation Analysis]
21 Zhang X, Liu D, Li M, Cao C, Wan D, Xi B, Li W, Tan J, Wang J, Wu Z, Ma D, Gao Q. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer. J Hematol Oncol 2017;10:29. [PMID: 28114995 DOI: 10.1186/s13045-017-0400-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]